The Study On The Developing Strategy Of GSK Chinese Vaccine Market

GlaxoSmithKline Co,2010 vaccine sales revenue of $6.7 billion,accounting for the global vaccine income nearly three into(29.1%),the first rank.Vaccine revenue in the company of all 15%of sales income,vaccine products in over 179 countries,2005-2010 sales revenue(excluding H1N1 vaccines)the average annual compound growth rate of 18%.With the continuous improvement of vaccine for emerging market governments pay much more attention to and the economic level,the size of the market will continue to expand.GSK vaccine products in emerging market share of 38%,accounting for the company's total revenue 21%vaccine.Because the GSK in the new market has established a good reputation and has a rich product line,with the coverage of countries and regions continue to increase in emerging markets,GSK vaccine business is expected to continue to maintain rapid growth.GSK vaccine in 1995 to enter the Chinese market,take a variety of forms of cooperation in China,in order to secure and expand market share.Before 2010,GSK has 10 vaccine products 14 product rules in China,2008 to 2010 annual growth rate of 19%,higher than the market average growth rate of 15%,achieved sales of 10.6million pounds.GSK in the Chinese market share as high as 28%,to become the market leader China vaccine.Along with the drug development is more and more difficult,due to patent medicine protection,global drug growth has been very weak,have the vaccine business of multinational pharmaceutical companies are very important to the future growth of the vaccine business,all of Chinese vaccine market look at fiercely as a tiger does.GlaxoSmithKline,Senauer Faye Basudeb,Pfizer,Novartis,the world's four largest vaccine manufacturers have gathered in Chinese,the vaccine business American Johnson and American Abbott also recently entered the Chinese market,and all the increase in China vaccine business investment.While local vaccine enterprise Chinese reaches as high as 36,is the world's most populous country vaccine manufacturers,isalso the largest production country,whether it is state-owned enterprises or private enterprises,are subject to national policy support and protection.Although the GSK in Chinese market share as high as 28%,but also the increasingly fierce industry competition.From the global vaccine industry point of view,the next few years vaccine market will maintain an average annual compound growth rate of more than 9.7%,in 2014 the market size will reach more than $3.5 billion.China vaccine market is one of the fastest growing markets in the world,I class and II class to market the vaccine respectively about 15%and 20%gjrowth rate,to 2014 will reach 1.0 billion and 2.3 billion yuan market.China 14 million population,about 1.7 million babies are born each year,Chinese has become the world's largest producer and user of the vaccine.Rely on the huge user base,Chinese will be vaccine strong recognition in the international market.The future,GSK blockbuster products rotavirus vaccine,HPV(cervical cancer vaccine)vaccine has completed phase Ⅲ clinical in China,is at the approval stage,is expected to market within 2 years.In the face of Chinese market challenges and opportunities,GSK is trying to adjust their market strategy.